18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

OBJECTIVE: The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could sig...

Bibliografski detalji
Glavni autori:	Vandenberghe, R, Van Laere, K, Ivanoiu, A, Salmon, E, Bastin, C, Triau, E, Hasselbalch, S, Law, I, Andersen, A, Korner, A, Minthon, L, Garraux, G, Nelissen, N, Bormans, G, Buckley, C, Owenius, R, Thurfjell, L, Farrar, G, Brooks, D
Format:	Journal article
Jezik:	English
Izdano:	2010

Slični predmeti

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
od: Vandenberghe, R, i dr.
Izdano: (2013)

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
od: Nelissen, N, i dr.
Izdano: (2009)

Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
od: Emma S. Luckett, i dr.
Izdano: (2023-01-01)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
od: Hugh G. Pemberton, i dr.
Izdano: (2023-05-01)

Abeta amyloid deposition in the language system and how the brain responds.
od: Nelissen, N, i dr.
Izdano: (2007)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
od: Mark R. Battle, i dr.
Izdano: (2018-12-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
od: Yong-Jin Park, i dr.
Izdano: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
od: Sanna Hellberg, i dr.
Izdano: (2019-03-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
od: Si Eun Kim, i dr.
Izdano: (2020-01-01)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
od: Lyduine E. Collij, i dr.
Izdano: (2023-11-01)

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
od: Westwood, S, i dr.
Izdano: (2018)

Author Correction: Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments
od: Soo Hyun Cho, i dr.
Izdano: (2021-03-01)

Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.
od: Koole, M, i dr.
Izdano: (2009)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
od: Sarah Westwood, i dr.
Izdano: (2018-12-01)

In vivo amyloid imaging in cortical superficial siderosis.
od: Dhollander, I, i dr.
Izdano: (2011)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
od: Milos D. Ikonomovic, i dr.
Izdano: (2018-06-01)

Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer’s Disease
od: Shizuo Hatashita, i dr.
Izdano: (2019-09-01)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents 18F-flutemetamol and 18F-florbetaben
od: Hye Joo Son, i dr.
Izdano: (2018-07-01)

Functional Changes in the Language Network in Response to Increased Amyloid β Deposition in Cognitively Intact Older Adults.
od: Adamczuk, K, i dr.
Izdano: (2014)

Anatomical based reconstruction of dynamic brain PET images using N-[11C]-methylpiperidin-4-YL-proprionate ([11C]-PMP) in elderly normals
od: Nelissen, N, i dr.
Izdano: (2007)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
od: Fiona Heeman, i dr.
Izdano: (2019-03-01)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
od: Young-Sil An, i dr.
Izdano: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
od: Taesik Yun, i dr.
Izdano: (2020-01-01)

Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
od: Val J. Lowe, i dr.
Izdano: (2017-01-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
od: Chan Ju Ryu
Izdano: (2022-12-01)

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.
od: Nordberg, A, i dr.
Izdano: (2013)

Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects
od: James M. Mountz, i dr.
Izdano: (2015-01-01)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
od: LEI Zhe, i dr.
Izdano: (2022-07-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
od: Hiroshi Matsuda, i dr.
Izdano: (2021-01-01)

Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers.
od: Adamczuk, K, i dr.
Izdano: (2013)

Computed Tomography Density and β-Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease: A 18F-Flutemetamol Positron Emission Tomography/Computed Tomography Study
od: Han Wu, i dr.
Izdano: (2022-03-01)

Cholinergic depletion and basal forebrain volume in primary progressive aphasia
od: Jolien Schaeverbeke, i dr.
Izdano: (2017-01-01)

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
od: Dietmar Rudolf Thal, i dr.
Izdano: (2019-11-01)

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia
od: Dietmar Rudolf Thal, i dr.
Izdano: (2020-08-01)

Drug development in Alzheimer’s disease: the contribution of PET and SPECT
od: Lieven Denis Herwig Declercq, i dr.
Izdano: (2016-03-01)

Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults
od: Emma S. Luckett, i dr.
Izdano: (2023-07-01)

Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases
od: Elin Lindström, i dr.
Izdano: (2020-01-01)

Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults
od: Emma S. Luckett, i dr.
Izdano: (2022-09-01)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.
od: Nina Schultz, i dr.
Izdano: (2019-01-01)

3D shape perception in posterior cortical atrophy: a visual neuroscience perspective
od: Gillebert, C, i dr.
Izdano: (2015)